Compare Meta Platforms Inc (META) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Novartis AG — how do they compare? Meta Platforms Inc trades at $647.69 (market cap $1.64T), while Novartis AG trades at $154.87 (market cap $290.25B). The key difference: Meta Platforms Inc is far larger — about 5.7× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| META | NVS | |
|---|---|---|
Market Cap | $1.64T | $290.25B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $168.62 |
52-Week Low | $525.72 | $113.50 |
Enterprise Value | $1.65T | $330.27B |
Dividend Yield | 0.33% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $647.42, up 0.22% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 23.49, net income margin of 32.84%, and consistent earnings beats. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, though it faces a youth addiction lawsuit in Massachusetts.
Outlook remains positive with analyst consensus at Buy (79.37%) and a $817.32 price target, supported by robust revenue growth and AI investments. Key risks include regulatory lawsuits and high capital expenditures. The stock presents a growth opportunity but requires monitoring of legal and competitive pressures.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
